PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE
Art Unit	1625
Examiner Name	Rita J Desai
Attorney Docket Number	NB 2020.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
RD	1	APFEL, C. M. et al. "Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents" *J. Med. Chem.* (2000) 43:2324-2331.	
RD	2	APFEL, C. M. et al. "Peptide deformylase as an antibacterial drug target: Assays for detection of its inhibition in *Escherichia coli* cell homogenates and intact cells" *Antimicrobial Agents and Chemotherapy.* (April 2001a) 45(4):1053-1057	
RD	3	APFEL, C.M. et al. "Peptide deformylase as an antibacterial drug target: Target validation and resistance development" *Antimicrobial Agents and Chemotherapy* (April 2001b) 45(4):1058-1064.	
RD	4	BECKER, A. et al. "Iron center, substrate recognition and mechanism of peptide deformylase" *Nat. Struc. Biol.* (December 1998) 5(12):1053-1058	
RD	5	CHAN, M. K. et al. "Crystal structure of the *Escherichia coli* peotide deformylase" *Biochemistry* (1997) 36:13904-13909	
RD	6	CHEN, D. Z. et al. "Actinonin , a naturally occurring antibacterial agent, is a potent deformylase inhibitor" *Biochemistry* (2000) 39:1256-1262	
RD	7	CLEMENTS, J. M. et al. "Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor" *Antimicrobial Agents and Chemotherapy* (February, 2001) 45(2):563-570	
RD	8	de GROOT, F. M. H. et al. "Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin" *J. Med. Chem.* (2000) 43:3093-3102	
RD	9	de GROOT, F.M.H. et al. "Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin" *J. Med. Chem.* (1999) 42(25):5277-5283	
RD	10	DUBOWCHIK, G. M. and R. A. Firestone "Cathepsin B-sensitive depeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin" *Bioor. & Med. Chem. Letts.* (1998) 8:3341-3346	
RD	11	DURAND, D. J. et al. "Peptide aldehyde inhibitors of bacterial peptide deformylases" *Archives of Biochemistry and Biophysics* (July 15, 1999) 367(2):297-302	
RD	12	GIGLIONE, C. et al. "Identification of eukaryotic peptide deformylases reveals universality of N-teminal protein processing mechanisms" *The EMBO Journal* (2000) 19(21):5916-5929	
RD	13	GIGLIONE, C. et al. "Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents" *Molecular Microbiology* (2000) 36(6):1197-1205	

Examiner's Signature	RDesai	Date Considered	6/8/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/714,255
Filing Date	November 14, 2003
First Named Inventor	Carlo BALLATORE
Art Unit	1625
Examiner Name	Rita J Desai
Attorney Docket Number	NB 2020.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
RD	14	HAO, B. et al. "Structural basis for the design of antibiotics targeting peptide deformylase" *Biochemistry* (1999) 38(15):4712-4719	
RD	15	HU, Y.-J. et al. "H-phosphonate derivatives as novel peptide deformylase inhibitors" *Bioor. & Med. Chem. Letts.* (1998) 8(18):2479-2482	
RD	16	HUNTINGTON, K. M. et al. "Synthesis and antibacterial activity of peptide deformylase inhibitors" *Biochemistry* (2000) 39(15):4543-4551	
RD	17	JAYASEKERA, M. M. K. et al. "Novel nonpeptidic inhibitors of peptide deformylase" *Archives of Biochem. and Biophy.* (September 15, 2000) 381(2):313-316	
RD	18	LACKEY, D. B. et al. "Enzyme-catalyzed therapeutic agent (ECTA) design: Activation of the antitumor ECTA compound NB 1011 by thymidylate synthase" *Biochem. Pharmocol.* (2001) 61:179-189	
RD	19	MEINNEL, T. "Vers une conception rationnelle de nouveaux agents antibactériens" *Path. Biol.* (Oct. 1999) 47(8):780-783	x
RD	20	MEINNEL, T. et al. "Methionine as translation start signal: A review of the enzymes of the pathway in *Escherichia coli*" *Biochemic* (1993) 75(12):1061-1075	
RD	21	RAGUSA S. et al. "Control of peptide deformylase activity by metal cations" *J. Mol. Biol.* (1998) 280:515-523	✓
RD	22	RAJAGOPALAN, P. T. R. and D. Pei "Oxygen-mediated inactivation of peptide deformylase" *Bio. Chem.* (August 28, 1998) 273(35):22305-22310	
RD	23	RAJAGOPALAN, P. T. R. et al. "Purification, characterization, and inhibition of peptide deformylase from *Escherichia coli*" *Biochem.* (1997) 36(45):13910-13918	
RD	24	WEI, Y. and D. Pei "Continuous spectrophotometric assay of peptide deformylase" *Analytical Biochem.* (1997) 250(1):29-34	
RD	25	WEI, Y. and D. Pei "Activation of antibacterial prodrugs by peptide deformylase" *Bioor. & Med. Chem. Letts.* (2000a) 10(10):1073-1076	
RD	26	WEI, Y. et al. "Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library" *J. Comb. Chem.* (2000b) 2(6):650-657	

Examiner's Signature	RDesai	Date Considered	6/8/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.